

Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease

Information for the public

Published: 20 July 2022

www.nice.org.uk

Imlifidase (Idefirix) is available on the NHS as a possible treatment to reduce antibodies that can cause kidney transplant rejection in adults if:

- they are waiting for a kidney transplant from a deceased donor
- their immune system reacts strongly to proteins called human leukocyte antigens (HLAs) on white blood cells from the potential donor (this is called being highly sensitised)
- they are unlikely to have a transplant in the current kidney allocation system
- only 1 dose of imlifidase is given
- treatment is done in a specialist centre that has experience of treating people who are highly sensitised to HLAs.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Kidney Care UK](#), 01420 541 424
- [Kidney Research UK](#), 0300 303 1100

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4675-4